375 related articles for article (PubMed ID: 15983555)
1. Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation.
Cutler C; Henry NL; Magee C; Li S; Kim HT; Alyea E; Ho V; Lee SJ; Soiffer R; Antin JH
Biol Blood Marrow Transplant; 2005 Jul; 11(7):551-7. PubMed ID: 15983555
[TBL] [Abstract][Full Text] [Related]
2. Risk factor analysis for thrombotic microangiopathy after reduced-intensity or myeloablative allogeneic hematopoietic stem cell transplantation.
Nakamae H; Yamane T; Hasegawa T; Nakamae M; Terada Y; Hagihara K; Ohta K; Hino M
Am J Hematol; 2006 Jul; 81(7):525-31. PubMed ID: 16755559
[TBL] [Abstract][Full Text] [Related]
3. Prophylaxis with sirolimus and tacrolimus ± antithymocyte globulin reduces the risk of acute graft-versus-host disease without an overall survival benefit following allogeneic stem cell transplantation.
Rosenbeck LL; Kiel PJ; Kalsekar I; Vargo C; Baute J; Sullivan CK; Wood L; Abdelqader S; Schwartz J; Srivastava S; Abonour R; Robertson MJ; Nelson RP; Cornetta K; Fausel CA; Farag SS
Biol Blood Marrow Transplant; 2011 Jun; 17(6):916-22. PubMed ID: 20932925
[TBL] [Abstract][Full Text] [Related]
4. Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial.
Platzbecker U; von Bonin M; Goekkurt E; Radke J; Binder M; Kiani A; Stoehlmacher J; Schetelig J; Thiede C; Ehninger G; Bornhäuser M
Biol Blood Marrow Transplant; 2009 Jan; 15(1):101-8. PubMed ID: 19135948
[TBL] [Abstract][Full Text] [Related]
5. Comparison of thrombotic microangiopathy after allogeneic hematopoietic cell transplantation with high-dose or nonmyeloablative conditioning.
Willems E; Baron F; Seidel L; Frère P; Fillet G; Beguin Y
Bone Marrow Transplant; 2010 Apr; 45(4):689-93. PubMed ID: 19718063
[TBL] [Abstract][Full Text] [Related]
6. Risk factors and severe outcome in thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation.
Uderzo C; Bonanomi S; Busca A; Renoldi M; Ferrari P; Iacobelli M; Morreale G; Lanino E; Annaloro C; Volpe AD; Alessandrino P; Longoni D; Locatelli F; Sangalli H; Rovelli A
Transplantation; 2006 Sep; 82(5):638-44. PubMed ID: 16969286
[TBL] [Abstract][Full Text] [Related]
7. Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and non-methotrexate-containing graft-versus-host disease prophylaxis regimens.
Cutler C; Li S; Kim HT; Laglenne P; Szeto KC; Hoffmeister L; Harrison MJ; Ho V; Alyea E; Lee SJ; Soiffer R; Sonis S; Antin JH
Biol Blood Marrow Transplant; 2005 May; 11(5):383-8. PubMed ID: 15846292
[TBL] [Abstract][Full Text] [Related]
8. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
Liu QF; Fan ZP; Zhang Y; Jiang ZJ; Wang CY; Xu D; Sun J; Xiao Y; Tan H
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296
[TBL] [Abstract][Full Text] [Related]
9. Thrombotic microangiopathy in transplantation and malignancy.
Qu L; Kiss JE
Semin Thromb Hemost; 2005 Dec; 31(6):691-9. PubMed ID: 16388420
[TBL] [Abstract][Full Text] [Related]
10. Transplant-associated microangiopathy in patients receiving tacrolimus following allogeneic stem cell transplantation: risk factors and response to treatment.
Oran B; Donato M; Aleman A; Hosing C; Korbling M; Detry MA; Wei C; Anderlini P; Popat U; Shpall E; Giralt S; Champlin RE
Biol Blood Marrow Transplant; 2007 Apr; 13(4):469-77. PubMed ID: 17382253
[TBL] [Abstract][Full Text] [Related]
11. Possible correlation of sirolimus plasma concentration with sinusoidal obstructive syndrome of the liver in patients undergoing myeloablative allogeneic hematopoietic cell transplantation.
Kiel PJ; Vargo CA; Patel GP; Rosenbeck LL; Srivastava S
Pharmacotherapy; 2012 May; 32(5):441-5. PubMed ID: 22499411
[TBL] [Abstract][Full Text] [Related]
12. High incidence of invasive aspergillosis associated with intestinal graft-versus-host disease following nonmyeloablative transplantation.
Labbé AC; Su SH; Laverdière M; Pépin J; Patiño C; Cohen S; Kiss T; Lachance S; Sauvageau G; Busque L; Roy DC; Roy J
Biol Blood Marrow Transplant; 2007 Oct; 13(10):1192-200. PubMed ID: 17889356
[TBL] [Abstract][Full Text] [Related]
13. Sirolimus as part of immunosuppressive therapy for refractory chronic graft-versus-host disease.
Jurado M; Vallejo C; Pérez-Simón JA; Brunet S; Ferra C; Balsalobre P; Pérez-Oteyza J; Espigado I; Romero A; Caballero D; Sierra J; Ribera JM; Díez JL
Biol Blood Marrow Transplant; 2007 Jun; 13(6):701-6. PubMed ID: 17531780
[TBL] [Abstract][Full Text] [Related]
14. Intestinal thrombotic microangiopathy after allogeneic bone marrow transplantation: a clinical imitator of acute enteric graft-versus-host disease.
Nishida T; Hamaguchi M; Hirabayashi N; Haneda M; Terakura S; Atsuta Y; Imagama S; Kanie T; Murata M; Taji H; Suzuki R; Morishita Y; Kodera Y
Bone Marrow Transplant; 2004 Jun; 33(11):1143-50. PubMed ID: 15077133
[TBL] [Abstract][Full Text] [Related]
15. Hyperglycemia during the neutropenic period is associated with a poor outcome in patients undergoing myeloablative allogeneic hematopoietic stem cell transplantation.
Fuji S; Kim SW; Mori S; Fukuda T; Kamiya S; Yamasaki S; Morita-Hoshi Y; Ohara-Waki F; Honda O; Kuwahara S; Tanosaki R; Heike Y; Tobinai K; Takaue Y
Transplantation; 2007 Oct; 84(7):814-20. PubMed ID: 17984832
[TBL] [Abstract][Full Text] [Related]
16. Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation.
Marty FM; Lowry CM; Cutler CS; Campbell BJ; Fiumara K; Baden LR; Antin JH
Biol Blood Marrow Transplant; 2006 May; 12(5):552-9. PubMed ID: 16635790
[TBL] [Abstract][Full Text] [Related]
17. Clinical impact of thrombotic microangiopathy on the outcome of patients with acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Cho BS; Min CK; Eom KS; Kim YJ; Kim HJ; Lee S; Cho SG; Kim Y; Kim DW; Lee JW; Min WS; Kim CC
Bone Marrow Transplant; 2008 May; 41(9):813-20. PubMed ID: 18209725
[TBL] [Abstract][Full Text] [Related]
18. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
19. Thrombotic microangiopathy following allogeneic bone marrow transplantation is associated with intensive graft-versus-host disease prophylaxis.
Paquette RL; Tran L; Landaw EM
Bone Marrow Transplant; 1998 Aug; 22(4):351-7. PubMed ID: 9722070
[TBL] [Abstract][Full Text] [Related]
20. Incidence, predisposing factors, and outcome of engraftment syndrome in pediatric allogeneic stem cell transplant recipients.
Schmid I; Stachel D; Pagel P; Albert MH
Biol Blood Marrow Transplant; 2008 Apr; 14(4):438-44. PubMed ID: 18342786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
